| References |
1. Bisogno G, Jenney M, Bergeron C, Melcón SG, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018 Jun 22. pii: S1470-2045(18)30337-1. doi: 10.1016/S1470-2045(18)30337-1. [Epub ahead of print] PubMed PMID: 29941280. 2. Kálmán J, Horváth T, Liktor B, Liktor B. A unique manifestation of Langerhans cell histiocytosis: Diagnostic and therapeutic considerations of atypical cases. Ear Nose Throat J. 2018 Apr-May;97(4-5):E13-E17. PubMed PMID: 29940687. 3. Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev. 2018 Jun 19;68:94-101. doi: 10.1016/j.ctrv.2018.06.013. [Epub ahead of print] Review. PubMed PMID: 29940525. 4. Maliszewska O, Plenis A, Olędzka I, Kowalski P, Miękus N, Bień E, Krawczyk MA, Adamkiewicz-Drożynska E, Bączek T. Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies. J Pharm Biomed Anal. 2018 Jun 19;158:376-385. doi: 10.1016/j.jpba.2018.06.031. [Epub ahead of print] PubMed PMID: 29936377. |
